COMPASS Pathways plc (CMPS)
- Previous Close
3.7600 - Open
3.7000 - Bid 2.7600 x 200
- Ask 4.7800 x 200
- Day's Range
3.7000 - 3.8700 - 52 Week Range
2.4900 - 8.5370 - Volume
308,717 - Avg. Volume
1,022,400 - Market Cap (intraday)
354.599M - Beta (5Y Monthly) 2.28
- PE Ratio (TTM)
-- - EPS (TTM)
-2.3000 - Earnings Date Jul 30, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.30
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
compasspathways.com166
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CMPS
View More
Performance Overview: CMPS
Trailing total returns as of 5/11/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMPS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMPS
View MoreValuation Measures
Market Cap
354.60M
Enterprise Value
221.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.29
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.11%
Return on Equity (ttm)
-81.55%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-155.12M
Diluted EPS (ttm)
-2.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
165.08M
Total Debt/Equity (mrq)
20.81%
Levered Free Cash Flow (ttm)
-66.77M